New drug targets lung inflammation in COPD patients

NCT ID NCT01463644

Completed Disease control Sponsor: McMaster University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tested mepolizumab, a drug that targets eosinophils (a type of white blood cell), in 18 COPD patients with eosinophilic bronchitis. The goal was to see if it reduces eosinophil levels in the airways and lowers the risk of severe flare-ups. Participants received either mepolizumab or a placebo monthly for six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mepolizumab
What this could lead to: If it works, this could point toward a treatment that reduces COPD flare-ups and the need for steroids in patients with high eosinophil levels.
What could go wrong: This is a small, early-phase trial with only 18 participants, so results may not apply broadly. The drug may not reduce exacerbations or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchitis chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHITIS CHRONIC AIRWAYS LIMITATION CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Contacts and locations

Show contact details

Locations

Firestone Institute of Respiratory Health, St Joseph's Hospital

Hamilton, Ontario, L8N 4A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.